These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34756581)

  • 1. Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.
    Ellebrecht CT; Maseda D; Payne AS
    J Invest Dermatol; 2022 Mar; 142(3 Pt B):907-914. PubMed ID: 34756581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of IgG subclasses and complement binding activity of autoantibodies from patients with bullous pemphigoid and pemphigus.
    Brooks WS; Lee YY; Abell E; Deng JS
    J Clin Lab Anal; 1989; 3(5):307-11. PubMed ID: 2681622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid.
    Dainichi T; Chow Z; Kabashima K
    J Dermatol Sci; 2017 Dec; 88(3):265-270. PubMed ID: 28747266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.
    Hammers CM; Stanley JR
    Annu Rev Pathol; 2016 May; 11():175-97. PubMed ID: 26907530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathologic mechanisms in pemphigus and bullous pemphigoid.
    Jordon RE; Kawana S; Fritz KA
    J Invest Dermatol; 1985 Jul; 85(1 Suppl):72s-78s. PubMed ID: 3891883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Clinical Trials in Pemphigus and Pemphigoid.
    Izumi K; Bieber K; Ludwig RJ
    Front Immunol; 2019; 10():978. PubMed ID: 31130959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of pemphigus vulgaris and bullous pemphigoid in the upper aerodigestive tract.
    Tabuchi K; Nomura M; Murashita H; Fujisawa Y; Tsuji S; Okubo H; Hara A
    Auris Nasus Larynx; 2006 Jun; 33(2):231-3. PubMed ID: 16168587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune Skin Conditions: Autoimmune Blistering Disease.
    Helm M; Helm LA; Clebak KT; Foulke G
    FP Essent; 2023 Mar; 526():13-17. PubMed ID: 36913658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the understanding and treatment of pemphigus and pemphigoid.
    Yamagami J
    F1000Res; 2018; 7():. PubMed ID: 30228865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclass characteristics of IgG autoantibodies in bullous pemphigoid and pemphigus.
    Shirakata Y; Shiraishi S; Sayama K; Miki Y
    J Dermatol; 1990 Nov; 17(11):661-6. PubMed ID: 2094743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B-cell epitope spreading without IgG subclass shifting.
    Recke A; Rose C; Schmidt E; Bröcker EB; Zillikens D; Sitaru C
    J Am Acad Dermatol; 2009 Aug; 61(2):333-6. PubMed ID: 19615544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.
    Amber KT; Maglie R; Solimani F; Eming R; Hertl M
    Drugs; 2018 Oct; 78(15):1527-1548. PubMed ID: 30238396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autoimmune bullous skin diseases].
    Joly P
    Rev Med Interne; 1999 Jan; 20(1):26-38. PubMed ID: 10220817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the autoimmune blistering response: a clinical and immunopathological shift from pemphigus foliaceus to bullous pemphigoid.
    Maeda JY; Moura AK; Maruta CW; Santi CG; Prisayanh PS; Aoki V
    Clin Exp Dermatol; 2006 Sep; 31(5):653-5. PubMed ID: 16901304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blistering diseases in the mature patient.
    Lakoš Jukić I; Jerković Gulin S; Marinović B
    Clin Dermatol; 2018; 36(2):231-238. PubMed ID: 29566927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
    Russo R; Cozzani E; Gasparini G; Parodi A
    Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutrition and bullous diseases.
    Stoj V; Lu J
    Clin Dermatol; 2022; 40(2):156-165. PubMed ID: 34808244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune bullous skin diseases, pemphigus and pemphigoid.
    Egami S; Yamagami J; Amagai M
    J Allergy Clin Immunol; 2020 Apr; 145(4):1031-1047. PubMed ID: 32272980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cell adhesion molecules and extracellular matrix components as target structures of autoimmunity].
    Moll R; Bahn H; Bayerl C; Moll I
    Verh Dtsch Ges Pathol; 1996; 80():67-79. PubMed ID: 9065056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.